Analysis of laboratory and instrumental markers of endothelial dysfunction in children with SARS-CoV-2 associated pneumonia and its relationship with the JAK2 V617F gene polymorphism
DOI:
https://doi.org/10.15574/PP.2025.2(102).8086Keywords:
children, SARS-CoV-2-associated pneumonia, endothelial dysfunction, JAK2 V617F gene polymorphismAbstract
SARS-CoV-2 may act as a trigger for the initiation of immunopathological processes such as endothelial dysfunction.
Aim - to determine the levels of endothelial dysfunction in children with SARS-CoV-2-associated pneumonia and to analyze its relationship with the JAK2 V617F gene polymorphism.
Materials and methods. The main study group included 160 children with SARS-CoV-2-associated pneumonia, while the control group comprised 40 healthy children. The main group was stratified by sex, age, severity of disease, levels of pro-inflammatory proteins, structural indices of the vascular wall, and functional measures of endothelial status. The presence of the JAK2 V617F gene polymorphism was assessed using polymerase chain reaction.
Results. The JAK2 V617F gene polymorphism was detected in 138 children (86.25±2.47%) with SARS-CoV-2-associated pneumonia and was significantly more frequent in those with severe disease. Among 132 children (82.5%) with pulmonary and extrapulmonary complications, 94 (95.9%) had a severe course of SARS-CoV-2-associated pneumonia. In children with complicated pneumonia, the JAK2 V617F gene polymorphism was diagnosed significantly more often. Children with SARS-CoV-2-associated pneumonia carrying the JAK2 V617F polymorphism demonstrated higher levels of C-reactive protein (by 42.95%), procalcitonin (by 19.01%), fibrinogen (by 14.89%), and D-dimer (by 34.53%), as well as elevated levels of interleukins 1 and 6, endothelin-1, and vascular endothelial growth factor (by 25.12%, 29.22%, 35.04%, and 36.12%, respectively). The mean value of flow-mediated dilation was significantly higher in children with severe SARS-CoV-2-associated pneumonia. Children with a non-severe course of pneumonia without the JAK2 V617F polymorphism had a 41.67% lower carotid intima-media thickness.
Conclusions. Children with SARS-CoV-2-associated pneumonia had a more severe course of disease, which correlated with the presence of the JAK2 V617F gene polymorphism. Severe pneumonia with pulmonary and extrapulmonary complications was more frequently observed in patients with the identified JAK2 V617F polymorphism.
The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the local institutional ethics committee. Informed consent was obtained from all participants.
The authors declare no conflict of interest.
References
Beckman JD, DaSilva A, Aronovich E, Nguyen A, Nguyen J, Hargis G et al. (2023, May). JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions. J Thromb Haemost. 21(5): 1366-1380. Epub 2023 Feb 2. https://doi.org/10.1016/j.jtha.2023.01.027; PMid:36738826 PMCid:PMC10246778
Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J et al. (2023). SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 21: 162-177. https://doi.org/10.1038/s41579-022-00841-7; PMCid:PMC9847462
Chen CC, Chen JL, Lin AJ, Yu LH, Hou HA. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis. Ann Hematol. 2024 Jun;103(6):1947-1965. Epub 2024 Apr 23. https://doi.org/10.1007/s00277-024-05754-4; PMid:38652240 PMCid:PMC11090937
Clinical management of COVID-19. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Іnterim guidance on 13 March 2020. URL: who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected; The final update of the COVID-19 Treatment Guidelines Special Considerations in Children was on February 29, 2024.
Deng X, Tang K, Wang Z, He S, Luo Z. (2024, Jun). Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity. J Epidemiol Glob Health. 14(2): 363-378. Epub 2024 Feb 20. https://doi.org/10.1007/s44197-024-00204-w; PMid:38376765 PMCid:PMC11176143
Gupta K, Kaur G, Pathak T, Banerjee I. (2022, Nov 30). Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 844: 146790. Epub 2022 Aug 17. https://doi.org/10.1016/j.gene.2022.146790; PMid:35987511 PMCid:PMC9384365
Kikkenborg Berg S, Palm P, Nygaard U, Bundgaard H, Petersen MNS, Rosenkilde S et al. (2022, Sep). Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, crosssectional study. Lancet Child Adolesc Health.;6(9):614-623. Epub 2022 Jun 23. PMCID: PMC9221683. https://doi.org/10.1016/S2352-4642(22)00154-7; PMid:35752194
Mehta P, Ciurtin C, Scully M, Levi M, Chambers RC. (2020). JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. European Respiratory Journal. 56(3): 2001919. https://doi.org/10.1183/13993003.01919-2020; PMid:32631841 PMCid:PMC7338400
Perner F, Perner C, Ernst T, Heidel FH. (2019, Aug 8). Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 8(8): 854. https://doi.org/10.3390/cells8080854; PMid:31398915 PMCid:PMC6721738
Zhang Y, Zhao Y, Liu Y, Zhang M, Zhang J. (2024, Dec15). New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms. Cancer. 130(24): 4229-4240. Epub 2024 Sep 14. https://doi.org/10.1002/cncr.35559; PMid:39277798
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal of Perinatology and Pediatrics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “Ukrainian Journal of Perinatology and Pediatrics” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license(СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
